By Matthew Pillar, Editor, BioProcess Online
Timothy Miller, Ph.D., is leading an effort to build one of the world’s largest AAV (adeno-associated virus) gene therapy manufacturing facilities. The cofounder and CEO of Columbus, OH-based Forge Biologics has been scratching the regenerative medicine leadership itch for quite a while now.
After a few years in the labs at Copernicus Therapeutics and Juventas Therapeutics, and a few more as product development lead at SironRX, he spent nearly seven years at the helm of Abeona Therapeutics after founding that company. If all that experience with clinical- stage organizations taught him anything, it’s that one key to longevity is a quick path to an elusive thing among clinical-stage biotechs: revenue.